Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018810 · ClinicalTrials.gov registry record · Phase 2
A Study for Adults With Plaque Psoriasis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01018810 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 8 participants.
The verdict
NCT01018810, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.
Interventions
- DRUG LY2525623 Intravenous
- DRUG LY2525623 Subcutaneous
- DRUG Placebo Intravenous
- DRUG Placebo Subcutaneous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01018810
The ClinicalTrials.gov registry entry for NCT01018810 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LY2525623 Intravenous is the first listed.
NCT01018810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01018810 about?
NCT01018810 is a clinical study titled "A Study for Adults With Plaque Psoriasis". In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.
What is the current status of trial NCT01018810?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2009-12. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01018810?
The interventions under investigation include: LY2525623 Intravenous (DRUG), LY2525623 Subcutaneous (DRUG), Placebo Intravenous (DRUG), Placebo Subcutaneous (DRUG).
Who is sponsoring clinical trial NCT01018810?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.